OneChain Immunotherapeutics secures €6.7M in pre-series A funding round
Summary
This funding comes three years after the creation of the company, during which the team has managed to take its most advanced product to clinical trials.OneChain Immunotherapeutics (OCI), a clinical stage biotech company focused on the development of CAR-T candidates for the treatment of oncological diseases, announces the closing of a 6.7 million pre-series A funding round. "It is an example of how the initiative of a non-profit foundation, with the leadership of private investors and the support of the government, can benefit patients, create jobs and advance science.This milestone is a significant step forward for the company, which will use the funding to consolidate its product pipeline and bring its innovative solutions to the clinical stage. "We are convinced of the enormous potential that CAR-T therapies pose for the treatment of cancer, and we strongly support the advances that OCI is making in this field," says Laura Rodriguez, principal at Invivo and advisor to OneChain. "We would like to welcome the new investors, who have placed their trust in the translational capacity of the OneChain team, and who will accompany us in this new phase to consolidate a portfolio of cell therapy products with the aim of improving the lives of patients," concludes Rodr\xedguez.In addition to the confidence placed in the company by private investors, OCI has received a financial injection from the European Innovation Council (EIC) through its Transition call, which promotes activities aimed at preparing the market launch of new technologies. The award of this project is the result of a very competitive process and speaks to the confidence that the European institutions have in the revolutionary potential of CAR-T therapy to transform cancer treatment.